MINNEAPOLIS--(BUSINESS WIRE)--April 13, 2006--MGI PHARMA, INC. (Nasdaq:MOGN - News), today announced that the New Drug Application (NDA) for Saforis(TM) (glutamine in UpTec(TM)) Powder for Oral Suspension has been submitted to the U.S. Food and Drug Administration (FDA) for review. Saforis, an oral formulation of glutamine in a proprietary delivery system designed to increase uptake of glutamine by the oral mucosa, is an investigational drug for the prevention and treatment of oral mucositis in patients receiving mucotoxic cancer therapy.
